Cover Image

Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis

Background: Hepatitis B, often leading to Hepatocellular carcinoma (HCC), poses a major global health challenge. While Tenofovir (TDF) and Entecavir (ETV) are potent treatments, their comparative effectiveness in improving recurrence-free survival (RFS) and overall survival (OS) rates in HBV-related...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jian-Xin Peng (Author), Ling-Zhi Wang (Author), Qiu-Ting Wang (Author), Hui-Long Li (Author), Li-Jun Lin (Author), Jun-Ming He (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A systematic review and meta-analysis comparing the impact of tenofovir and entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma patients undergoing liver resection
by: Lingbo Hu, et al.
Published: (2024)

Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B
by: Beatriz López Centeno, et al.
Published: (2016)

Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024)

Comparative effectiveness of tenofovir versus entecavir in patients with hepatitis B virus-related cirrhosis in Taiwan: a retrospective cohort study
by: Yu-Han Huang, et al.
Published: (2023)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
by: Yang YM, et al.
Published: (2017)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
by: Suzuki F, et al.
Published: (2014)

Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir
by: Diana Horta, et al.

Clinical utility of entecavir for chronic hepatitis B in Chinese patients
by: Wang JY
Published: (2013)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
by: Yan Huang, et al.
Published: (2022)

Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection
by: Kai-Chi Chang, et al.
Published: (2016)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
by: Wang G, et al.
Published: (2015)

Constipation during Entecavir treatment in Chronic Hepatitis B patients: Two Cases Reports
by: Meng-Lan Wang, et al.
Published: (2017)

Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats
by: Tao Yang, et al.
Published: (2020)

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
by: Lanqing Li, et al.
Published: (2023)

Effects of Clonorchis sinensis combined with Hepatitis B virus infection on the prognosis of patients with Hepatocellular Carcinoma following Hepatectomy.
by: Yuan-Kuan Li, et al.
Published: (2023)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018)

Prognosis of hepatocellular carcinoma metastasizing to the oral cavity
by: Jun-Hee Hong, et al.
Published: (2021)

Low-dose prednisone plus entecavir in the treatment of hepatitis B virus associated glomerulonephritis with massive proteinuria: a report of 3 cases
by: Yuan-yuan Liu, et al.
Published: (2024)

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
by: Tsai N, et al.
Published: (2012)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
by: Yi He, et al.
Published: (2022)

Huge fetal hepatic Hemangioma: prenatal diagnosis on ultrasound and prognosis
by: Li Jiao-ling, et al.
Published: (2018)

Tenofovir and its potential in the treatment of hepatitis B virus
by: Laura Reynaud, et al.
Published: (2009)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
by: Andrew Hill, et al.
Published: (2015)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
by: Yim HJ, et al.
Published: (2022)

Integrating machine learning to construct aberrant alternative splicing event related classifiers to predict prognosis and immunotherapy response in patients with hepatocellular carcinoma
by: Wangrui Liu, et al.
Published: (2022)

The Correlation of Centromere Protein Q with Diagnosis and Prognosis in Hepatocellular Carcinoma
by: He K, et al.
Published: (2024)

Effects of Glycolysis-Related Genes on Prognosis and the Tumor Microenvironment of Hepatocellular Carcinoma
by: Ju-Yan Zheng, et al.
Published: (2022)

Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
by: Fei-lin Ge, et al.
Published: (2021)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021)

Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models
by: Xiaodan Hong, et al.
Published: (2022)

Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation
by: Yue Ming, et al.
Published: (2020)

Is increasing the dose of Entecavir effective in partial virological responders?
by: Erturk A, et al.
Published: (2014)

Entecavir: A Review and Considerations for Its Application in Oncology
by: Tânia Lourenço, et al.
Published: (2023)

The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease
by: Zhu LY, et al.
Published: (2016)

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
by: Man Li, et al.
Published: (2023)

ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis
by: Xuan Wang, et al.
Published: (2023)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
by: Aida N. Kawuma, et al.
Published: (2023)

An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma
by: Zhonghai Du, et al.
Published: (2024)

Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis
by: Tian X, et al.
Published: (2015)

Validated spectrometric determination of penciclovir and entecavir in bulk and in pharmaceutical preparations
by: Asmaa A. Elzaher, et al.
Published: (2016)